申请人:Takeda Pharmaceutical Company Ltd.
公开号:US07973163B2
公开(公告)日:2011-07-05
The present invention aims at provision of a quinoline derivative having a neurokinin 2 (NK2) receptor antagonistic action and relates to a compound represented by the formula (I)
wherein R1 is a hydrogen atom and the like; R2 is a hydrogen atom, a hydrocarbon group optionally having substituent(s) and the like; R3 is unsubstituted (i.e., absence), a hydrogen atom and the like; R4 and R5 are the same or different and each is a hydrogen atom, a hydrocarbon group optionally having substituent(s), and the like; R6 is (cyclic group optionally having substituent(s))-carbonyl, and the like; R7, R8, R9 and R10 are the same or different and each is a hydrogen atom, halogen and the like; or R7 and R8, R8 and R9, and R9 and R10 may form a ring together with the adjacent carbon atoms; n is an integer of 1 to 5;
--- represents unsubstituted (i.e., absence) or a single bond; and
represents a single bond or a double bond, or a salt thereof, and the like.
本发明旨在提供一种具有神经激肽2(NK2)受体拮抗作用的喹啉衍生物,并涉及一种由式(I)表示的化合物,其中R1是氢原子等;R2是氢原子、烃基可选地具有取代基等;R3是未取代的(即不存在)、氢原子等;R4和R5相同或不同,每个都是氢原子、烃基可选地具有取代基等;R6是(环状基团可选地具有取代基)-羰基等;R7、R8、R9和R10相同或不同,每个都是氢原子、卤素等;或R7和R8、R8和R9、R9和R10可以与相邻的碳原子一起形成环;n是1到5的整数;---表示未取代(即不存在)或单键;表示单键或双键,或其盐等。